Clinical trials: Solid Tumors, Adult
Cachexia, Lymphoma
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients.
- Conditions
- Cachexia, Lymphoma, Melanoma (Skin), Ovarian Cancer
- Trial name
- NCT00093678
- Testing
- celecoxib, anticachectic therapy, nutritional support
- Sponsor
- Eastern Cooperative Oncology Group
Solid Tumor, Adult
Safety Study of 177Lu-Anti-ED-B mAbs SPECT Imaging in Patients With ED-B Positive Solid Tumors
This is a single arm study to evaluate the safety and biodistribution of 177Lu-labeled anti-ED-B mAbs SPECT imaging in patients with ED-B positive solid tumors.
- Trial name
- NCT05623891
- Testing
- 177Lu-B5-IgG4
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Refractory Cancer, Recurrent Cancer
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
This study will evaluate the safety, tolerability, and pharmacokinetics of RO7617991, and will make a preliminary assessment of the anti-tumor activity of RO7617991 in human leukocyte antigen (HLA)-A*02 eligible patients with…
- Conditions
- Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- Trial name
- NCT06372574
- Testing
- RO7617991, Tocilizumab
- Sponsor
- Genentech, Inc.
Adult Solid Neoplasm, Lymphoma
Improving Communication in Older Cancer Patients and Their Caregivers
Over 60% of cancers occur in older persons, and the number of older persons with cancer is expected to grow as the population ages.
- Trial name
- COACH (NCT02107443)
- Testing
- Geriatric Assessment Summary, Geriatric Assessment Targeted Recommendations, Geriatric Assessment (GA)
- Where
- 19 sites in United States
- Volunteers
- 546 people, healthy volunteers welcome
- Sponsor
- Supriya Mohile
Solid Tumor, Adult, NSCLC
Study to Evaluate D-1553 in Subjects With Solid Tumors
This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with…
- Conditions
- Solid Tumor, Adult, NSCLC, CRC
- Trial name
- NCT04585035
- Testing
- D-1553, D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other
- Where
- 25 sites in United States, Australia and 2 more
- Volunteers
- 180 people
- Sponsor
- InventisBio Co., Ltd
Solid Tumor, Adult
Study of FCN-437c in Patients With Advanced Solid Tumors
This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.
- Trial name
- FCN-437c (NCT03951116)
- Testing
- FCN-437
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Fochon Pharmaceuticals, Ltd.
Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
This phase I trial studies the side effects and the best dose of PI3K inhibitor BKM120 when given together with cisplatin and etoposide in treating patients with advanced solid tumors or small cell lung cancer.
- Trial name
- NCT02194049
- Testing
- BKM120, cisplatin, etoposide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of California, Davis
Adrenocortical Carcinoma, Breast Cancer
Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT00003038
- Testing
- doxorubicin hydrochloride, suramin
- Where
- United States
- Sponsor
- Mayo Clinic
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor
- Trial name
- NCT04161391
- Testing
- TPX-0046
- Where
- 21 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Turning Point Therapeutics, Inc.
Metastatic Cancer, Pain
Percutaneous Cryoablation in Treating Patients With Painful Bone Metastases
RATIONALE: Percutaneous cryoablation may help relieve pain caused by bone metastases. PURPOSE: This clinical trial is studying the side effects and how well percutaneous cryoablation works in treating patients with painful bone…
- Conditions
- Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00608855
- Testing
- questionnaire administration, cryosurgery, pain therapy
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Solid Tumor, Adult, Advanced Solid Tumors
IMX-110 in Patients With Advanced Solid Tumors
Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for the recommended phase 2 dose (RP2D) of IMX-110.
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumors, Pancreatic Cancer, Breast Cancer
- Trial name
- NCT03382340
- Testing
- Imx-110
- Where
- 2 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Immix Biopharma Australia Pty Ltd
Solid Tumor, Adult, Non-small Cell Lung Cancer
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
- Trial name
- NCT04913285
- Testing
- KIN-2787, KIN-2787 and binimetinib
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 400 people
- Sponsor
- Pierre Fabre Medicament
Solid Tumors
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
The purpose of this study is to enable patients with solid tumors, who received anetumab ravtansine in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed.
- Trial name
- NCT03926143
- Testing
- BAY94-9343 (Anetumab ravtansine)
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 9 people
- Sponsor
- Bayer
Unspecified Adult Solid Tumor, Protocol Specific
Etoposide and Celecoxib in Patients With Advanced Cancer
RATIONALE: Etoposide and celecoxib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving more than 1 drug may be an effective treatment for advanced cancer.
- Trial name
- NCT00551005
- Testing
- celecoxib, etoposide, immunoenzyme technique
- Volunteers
- 58 people
- Sponsor
- City of Hope Medical Center
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Cancer
Phase I trial to study the effectiveness of combining flavopiridol, fluorouracil, and leucovorin with or without irinotecan in treating patients who have advanced cancer.
- Trial name
- NCT00021073
- Testing
- alvocidib, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Octreotide in Treating Patients With Cancer-Related Malignant Ascites
RATIONALE: Octreotide may be an effective treatment for malignant ascites. It is not yet known whether octreotide is more effective than a placebo in treating malignant ascites.
- Trial name
- NCT00182754
- Testing
- octreotide acetate
- Where
- 122 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
BMS-214662 in Treating Patients With Solid Tumors
Phase I trial to study the effectiveness of BMS-214662 in treating patients who have solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
- Trial name
- NCT00005973
- Testing
- BMS-214662, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Malignancies
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors
This study will study the safety, tolerability and metabolism of a drug called HSP990 when given by mouth once a week or twice weekly to subjects with advanced solid tumors.
- Trial name
- NCT00879905
- Testing
- HSP990
- Where
- 3 sites in Canada, France and 1 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Unspecified Adult Solid Tumor, Protocol Specific
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic
This phase I trial studies the side effects and best dose of PI3K inhibitor BKM120 when given together with docetaxel in treating patients with advanced solid tumor that is locally advanced, cannot be removed by surgery, or…
- Trial name
- NCT01540253
- Testing
- PI3K inhibitor BKM120, docetaxel, pharmacological study
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Roswell Park Cancer Institute
Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
MEN-10755 in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MEN-10755 in treating patients who have solid tumors.
- Trial name
- NCT00003982
- Testing
- sabarubicin
- Where
- 27 sites in Austria, Belgium and 7 more
- Volunteers
- 30 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.